Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002447 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Two Anti-HIV Drug Combinations
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 146
- Enrollment target
NCT00002447: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00002447 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 146 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002447, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 146 participants
- Enrollment target
Study Summary
The purpose of this study is to compare 2 anti-HIV drug combinations.
Interventions
- DRUG Ritonavir
- DRUG Efavirenz
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 1999-10 |
| Phase | Phase 3 |
What the finished NCT00002447 record still lists
NCT00002447 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT00002447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002447 about?
NCT00002447 is a clinical study titled "A Study to Compare Two Anti-HIV Drug Combinations". The purpose of this study is to compare 2 anti-HIV drug combinations.
What is the current status of trial NCT00002447?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 146 participants. The study started on 1999-10.
What interventions are being tested in trial NCT00002447?
The interventions under investigation include: Ritonavir (DRUG), Efavirenz (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002447?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002447's enrollment target sits among peer trials
146 1551st of 2000 higher than 446 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia